Recall Register

Drug recall: Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kits containing…

Class II FDA enforcement event 98810. Recall start date: . Status in the FDA record: Ongoing.

Reason for recall, in the words of FDA

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

Teva Pharmaceuticals USA, Inc started this drug recall on 24 Apr 2026. The firm address in the FDA record is in Parsippany, NJ. FDA put the recall in Class II. FDA event 98810 has 1 product record. The first FDA enforcement report date is 13 May 2026. The record gives the status Ongoing.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide in the USA

Recalling firm

Teva Pharmaceuticals USA, Inc, Parsippany, NJ.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 98810: product records
Recall numberProductQuantityClassStatusReport date
D-0519-2026Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kits containing: 8-mL vial of 30 mg strength, a pre-filled syringe containing 2 mL of diluent, one vial adapter, and one sterile 1¿ 19-gauge safety injection needle, Rx only, Manufactured in Greece BY: Pharmathen…2,200 kitsClass IIOngoing13 May 2026

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Drug events that started in 2026
234
Share of these events in Class II
74%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
60

Other events of the firm

Other FDA enforcement events of Teva Pharmaceuticals USA, Inc
InitiatedProduct (first record)TypeClassRecords
24 Aug 2026traZODone Hydrochloride Tablets, USP, 50 mg, Rx only, 100 Tablets, Manufactured in Croatia By: Pliva Hrvatska d.o.o, ZagDrugClass II1
6 Apr 2026Claravis (isotretinoin capsule, USP), 10 mg, Packaged as a) 100-count carton, NDC 0555-1054-56, with 10x10 blister packsDrugClass II1
19 Mar 2026Clonidine Transdermal System, USP, 0.1 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers, Rx Only, ManufactDrugClass II3
17 Mar 2026Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial in Kit, Rx onlDrugClass II3
29 Jan 2026Metoprolol Succinate Extended-Release Tablets, 25 mg, 100 tablets bottles (NDC: 45963-709-11) and 1,000 tablets bottles DrugClass II4
12 Jan 2026Isotretinoin Capsules, USP, 30 mg, Rx Only, 10 count Prescription Pack, Manufactured for: Teva Pharmaceuticals USA, Inc.DrugClass II2
7 Nov 2025Carton label: Testosterone Gel 1%, 2.5 grams per unit dose, CIII, 30 unit-dose packets, Rx only, Manufactured by: ActaviDrugClass III1
13 Oct 2025Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx oDrugClass II1
7 Oct 2025Prazosin Hydrochloride, Capsules, USP, 1 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 194DrugClass II3
23 May 2025Metoclopramide Tablets, USP 10 mg, 100-count bottle, Rx only, Manufactured in Croatia by Pliva Hrvatska, d.o.o., Zageb, DrugClass II1

Teva Pharmaceuticals USA, Inc: all 60 events

Official channels

Cite this page

Recall Register. FDA enforcement event 98810. https://recallregister.com/fda/ii/98810/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide in the USA
What quantity of product is in FDA event 98810?
The FDA record gives this quantity: 2,200 kits
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2026 have the same class?
74% of the 234 drug events that started in 2026 are in Class II.